Overview

* Treace Medical Q2 2025 revenue rises 7%, beating analyst expectations, per LSEG data

* Net loss improved by 18% to $17.4 mln, adjusted EBITDA loss reduced by 58%

* Expanded bunion technology portfolio with new systems and increased patent holdings

Outlook

* Treace reaffirms 2025 revenue guidance of $224 mln to $230 mln

* Company expects breakeven Adjusted EBITDA for full-year 2025

* Treace projects 50% reduction in cash usage for 2025

Result Drivers

* TECHNOLOGY EXPANSION - Release of Nanoplasty, Percuplasty, and SpeedMTP systems contributed to revenue growth

* OPERATING EFFICIENCIES - Reduction in operating expenses helped improve net loss figures

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $47.39 $47.10

Revenue mln mln (6

Analysts

)

Q2 EPS -$0.28

Q2 Gross 79.7%

Margin

Q2 Gross $37.75

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Treace Medical Concepts Inc ( TMCI ) is $9.00, about 39.2% above its August 6 closing price of $5.47

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)